SOLICITATION NOTICE
D -- Statistical Software and associated support - RFQAttachmentNo.1 - SOW
- Notice Date
- 8/21/2018
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 511120
— Periodical Publishers
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services - Rockville, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001, United States
- ZIP Code
- 20857-0001
- Solicitation Number
- FDA-RFQ-18-1198451
- Archive Date
- 9/12/2018
- Point of Contact
- Jody L. OKash, Phone: 2404024996
- E-Mail Address
-
jody.okash@fda.hhs.gov
(jody.okash@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Cytel Statistical Software or Equivalent SOW i. This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented by Part 13 and additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued. ii. The solicitation number is FDA-RFQ-18-1198451. This is a Request for Quotation (RFQ) under Part 13. iii. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-99. iv. This RFQ is unrestricted. The NAICS code is 511210, size standard $38.5M. v. This is a brand name or equal to RFQ for the renewal of Cytel statistical software, maintenance, and technical support or equivalent products and associated support. FDA researchers currently use Cytel Software to analyze clinical trials, observational studies, animal studies, bioequivalence determinations, and chemical and manufacturing controls.. Description: This Request for Quote (RFQ) is to set up a Definitive order for a 12-month base period and two 12-month option periods to purchase the following Cytel Statistical Software and maintenance or equivalent products and associated maintenance / support: • StatXact 11.1 • LogXact 11.1 • StatXact Procs (at least version 11.1) • EAST 6.4 Premium Edition (including all available modules) vi. The FAR provisions at 52.212-1, Instructions to Offerors -- Commercial, 52.212-3, Offeror Representations and Certifications -Commercial Items, and 52.209-5, Certification Regarding Responsibility Matters apply to this acquisition. As a reference, Clause 52.212-1 section (b) of which described the form and content of submissions/quotes, and which Quoters shall follow, is the following: (b) Submission of Quotes. Submit signed and dated electronic quotes to the Contracting Officer, Jody O'Kash via email at jody.okash@fda.hhs.gov before the exact time specified in this solicitation. The subject line of the email shall include the following: RFQ Number: FDA-RFQ-18-1198451, Project Title: StatisticalSoftware_Cytelorequivalent_ Company Name TECHNICAL QUOTES AND EVALUATION: Equal to quotes must meet all the technical requirements and Salient Characteristics identified in Section 4 of the SOW in order to be considered technically acceptable. In order to be considered an equal solution, an alternative solution must be compatible with the technical requirements discussed in Section 4. For the purposes of this RFQ, FDA defines compatible as meaning that there will be no communication, performance, maintainability issues in the interconnection of solutions with different configurations. Equal to quotes must submit a separate Technical quote with a detailed point-by-point description of how the equal to products meet all the technical requirements/salient characteristics of this SOW. Quotes with the specified Cytel Software products and associated maintenance support services meeting all the salient characteristics of this SOW are not required to submit separate Technical Quotes. Technical quotes shall not contain pricing information. Quoters shall submit all applicable terms and conditions in full text as attachments, appendix, or exhibits. Quoters are advised that additional terms and conditions submitted with their quotations that are in conflict with the terms and conditions of this solicitation may be deemed as technically unacceptable and as such not be considered for award. All Quoters providing quotations must clearly state the overall cost to the Government. Quotes shall be valid through September 30, 2018. Quoters shall submit all assumptions in their quotations. Quoters shall notify the Contract Specialist / Contracting Officer immediately if this requirement is registered by a reseller with the Original Equipment Manufacturer (OEM). 508 Compliance Per HHSAR 352.239-73, Electronic Information and Technology Accessibility, all Quoters must complete and submit a Voluntary Product Accessibility Templates (VPAT). The following 508 sections apply to the Cytel Software: Appendix A: Scoping E203 Access to Functionality E204 Functional Performance Criteria E205 Electronic Content E207 Software E208 Support Documentation Services BUSINESS QUOTE INSTRUCTIONS The Quoter shall submit a breakdown of pricing for Cytel Software components or equivalent products for a 12-month base period and two 12-month Option Periods. Pricing for each period shall include unit pricing for StatXact 11.1, LogXact 11.1, StatXact Prcos, and EAST 6.4 Premium Edition. The submitted business quotation shall at a minimum contain the following for each Cytel product: Product No. or equivalent, Product Description or equivalent, Qty, Unit Price, Subtotal, vii. Per FAR 52.212-3(b) Offeror Representations and Certifications-Commercial Items (Nov 2017) applies to this solicitation. By submission of a quote in response to this RFQ, the Quoter verifies that the representations and certifications currently posted at sam.gov are current accurate complete and applicable to this solicitation (including the business size standard applicable to the NAICS code referenced for this solicitation), as of the date of this offer and are incorporated in this offer by reference (see FAR 4.1201), with exceptions, if any, identified by paragraph. Therefore, Quoters shall not submit documentation of their representations and certifications in response to this quote, excluding exceptions. viii. FAR Provision 52.212-2 - Evaluation - Commercial Items applies to this solicitation. (a) FDA will evaluate all quotes received in response to this RFQ by using the lowest-price-technically-acceptable (LPTA) methodology. Quotes must meet all the functional characteristics and requirements of this solicitation in order to be considered technically acceptable. FDA will issue the award to the Quoter whose proposed solution meets all technical requirements, including the Terms and Conditions identified within the solicitation, and whose overall price is lowest. Quoters are advised that additional terms and conditions submitted with their quotation that are in conflict of the terms and conditions of this solicitation may be deemed technically unacceptable and may not be considered for award. (b) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful Quoter within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (End of Provision) ix. The following FAR Provisions are incorporated by reference and apply to this solicitation: 52.209-7 Information Regarding Responsibility Matters. (Jul 2013) 52.204-7 System for Award Management (Jul 2013), 52.225-25 x. Please see RFQ Attachment No. 1: Statistical Software SOW for a list of FDA, HHSAR, and FAR clauses that apply to this action. xi. Questions - It shall be the obligation of the Quoter to exercise due diligence to discover and to bring to the attention of the Contracting Officer (CO) at the earliest possible time, any ambiguities, discrepancies, inconsistencies, or conflicts between the statement of work and other documents attached hereto or incorporated by reference herein. Questions shall be e-mailed to jody.okash@fda.hhs.gov no later than 04:00pm Eastern Time (local), August 23, 2018. The closing date will not be extended for the purpose of responding to questions received after this date. xii. The quotations shall be submitted electronically via email to jody.okash@fda.hhs.gov by Tuesday, August 28th at 4pm Eastern time (local).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA-RFQ-18-1198451/listing.html)
- Place of Performance
- Address: TBD, United States
- Record
- SN05047409-W 20180823/180821231017-37cf42b3ea40dd10eae891c0599b14cc (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |